While the FDA has approved use of the 4 assay systems as complementary diagnostics in some tumor types (eg, PD-L1 IHC 28–8 pharmDx with nivolumab for HNSCC and UC), the European Medicines Agency does not recognize complementary diagnostic assays for use with immune checkpoint inhibitors. The gene discussed is CD274; the disease is neoplasm.